Pharming Group NV
$ 10.95
0.92%
07 Aug - close price
- Market Cap 767,943,000 USD
- Current Price $ 10.95
- High / Low $ 11.15 / 10.89
- Stock P/E 77.50
- Book Value 3.61
- EPS 0.14
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.04 %
- 52 Week High 21.34
- 52 Week Low 9.62
About
Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.
Analyst Target Price
$34.35
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-05-07 | 2026-03-12 | 2025-11-06 | 2025-07-31 | 2025-05-08 | 2025-03-13 | 2024-10-24 | 2024-08-01 | 2024-05-08 | 2024-03-14 | 2023-10-26 |
| Reported EPS | 0.02 | -0.07 | 0.07 | 0.01 | 0.01 | -0.02 | 0.005 | -0.0153 | -0.0177 | -0.02 | -0.0406 | 0.01 |
| Estimated EPS | 0.2 | 0.01 | 0.0117 | -0.125 | -0.01 | -0.02 | 0.0085 | -0.0025 | -0.002 | 0.01 | 0.0045 | -0.01 |
| Surprise | -0.18 | -0.08 | 0.0583 | 0.135 | 0.02 | 0 | -0.0035 | -0.0128 | -0.0157 | -0.03 | -0.0451 | 0.02 |
| Surprise Percentage | -90% | -800% | 498.2906% | 108% | 200% | 0% | -41.1765% | -512% | -785% | -300% | -1002.2222% | 200% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHAR
2026-08-06 09:42:04
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Pharming Group N.V. (PHAR) following a significant drop in its stock price. This comes after the company reported a 3% year-over-year revenue decline in Q2 2026 and lowered its full-year guidance, largely due to weaker-than-expected RUCONEST sales. The investigation focuses on whether Pharming Group adequately disclosed competitive and demand pressures affecting RUCONEST before revising its guidance, which led to a 22% stock price drop.
2026-08-05 15:16:00
The Law Offices of Frank R. Cruz have announced a securities fraud investigation into Pharming Group N.V. (PHAR) on behalf of investors who lost money. The investigation follows a 10.5% stock drop after the company reported a 3.2% year-over-year revenue decline and cut its full-year revenue guidance. Shareholders are urged to contact the law firm to learn about potentially pursuing a claim.
2026-08-05 07:10:14
Pharming Group NV discussed its Q2/1H 2026 results on a July 30 call, attended by CEO Fabrice Chouraqui and other key executives. The company cut its full-year revenue guidance to USD 375 million-USD 395 million, while lowering its operating expense outlook. Q2 revenue was USD 90.2 million, with Joenja showing significant growth, and a return to growth for RUCONEST is expected in H2.
2026-08-05 07:10:13
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Pharming Group N.V. (NASDAQ: PHAR) after the company reported a decline in Q2 2026 revenue and lowered its full-year guidance, primarily due to weaker RUCONEST sales. The firm is encouraging investors who purchased Pharming Group securities to contact them to learn more about potential claims regarding the company's disclosure practices. The investigation focuses on whether Pharming Group adequately disclosed competitive pressures affecting RUCONEST before its stock dropped 22% following the news.
2026-08-04 11:40:12
This article analyzes Pharming Group N.v. (NASDAQ: PHAR), highlighting weak near and mid-term sentiment and a neutral long-term outlook. It presents AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report emphasizes the elevated downside risk due to the absence of additional long-term support signals.
2026-08-04 08:56:00
Pharming Group NV released the transcript of its Q2/1H 2026 results call, where the company discussed its financial performance and future outlook. The full-year revenue guidance was cut to $375 million-$395 million, and the operating expense outlook was lowered to $315 million-$320 million. Key drugs RUCONEST and Joenja showed mixed results, with RUCONEST revenue down but Joenja revenue up significantly, and new drug applications are underway.
